Table 2.
Effects of atorvastatin 80 mg and rosuvastatin 40 mg on laboratory parameters after 4-week treatment
| Atorvastatin 80 mg, n=33 | Rosuvastatin 40 mg, n=30 | |||||
|---|---|---|---|---|---|---|
| Baseline | 4th week of the therapy | P-value | Baseline | 4th week of the therapy | P-value | |
| TC, mg/dL | 181.64±35.42 | 138.36±34.08 | <0.001 | 206.33±36.00 | 143.27±39.95 | <0.001 |
| LDL-C, mg/dL | 120.08±27.68 | 72.22±25.09 | <0.001 | 131.69±24.61 | 69.06±26.62 | <0.001 |
| HDL-C, mg/dL | 36.33±9.76 | 36.73±9.62 | 0.665 | 37.60±10.72 | 38.84±10.14 | 0.323 |
| TC/ HDL-C | 5.26±1.56 | 3.88±0.95 | <0.001 | 5.80±1.55 | 3.81±1.04 | <0.001 |
| Triglyceride, mg/dL | 116.00 (87.00–182.00) | 110.00 (89.00–154.00) | 0.532 | 154.50 (125.75–215.75) | 135.00 (91.00–182.50) | 0.052 |
| Oxidized-LDL, ng/mL | 870.39±239.35 | 742.61±189.83 | <0.001 | 862.20±331.87 | 703.87±186.00 | <0.001 |
| ALT, IU/L | 27.21±14.51 | 25.70±11.15 | 0.461 | 27.30±14.14 | 28.67±19.87 | 0.710 |
| AST, IU/L | 33.85±15.80 | 30.18±12.24 | 0.118 | 30.57±13.84 | 30.20±21.31 | 0.925 |
| CK, IU/L | 118.97±23.82 | 121.24±38.42 | 0.759 | 114.77±28.47 | 122.63±57.47 | 0.483 |
| Endocan, pg/mL | 110.27 (86.03–143.69) | 99.22 (78.30–122.87) | 0.242 | 110.73 (77.28–165.22) | 93.40 (70.48–115.13) | 0.014 |
| Chemerin, ng/mL | 264.90 (196.00–525.95) | 135.00 (105.95–225.65) | <0.001 | 309.95 (168.87–701.27) | 121.25 (86.60–212.65) | <0.001 |
| Galectin-3, ng/mL | 17.10 (13.10–22.25) | 19.30 (15.25–23.45) | 0.721 | 18.25 (12.82–23.82) | 16.60 (10.60–20.15) | 0.074 |
| WBC, 103/µL | 10.24±2.62 | 8.1.±1.83 | <0.001 | 10.59±3.09 | 7.71±1.46 | <0.001 |
ALT - alanine aminotransferase; AST - aspartate aminotransferase; CK - creatine kinase; HDL-C - high-density lipoprotein cholesterol; LDL-C - low-density lipoprotein cholesterol;
TC - total cholesterol; Oxidized-LDL - oxidized low-density lipoprotein cholesterol; WBC - white blood cells